
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
ALK-1 receptor: New target in angiogenesis
Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).
Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).
Articles in this issue
over 16 years ago
ADT in prostate ca increases risk of bone and heart complicationsover 16 years ago
Abraxis backs SPARC as prognostic biomarkerover 16 years ago
Abraxane prolongs PFS in metastatic diseaseover 16 years ago
SAVI applicator removes obstacles associated with brachytherapyover 16 years ago
Mistrust, costs reduce breast cancer screening among minoritiesover 16 years ago
Oral chemotherapy poses more challenges for cancer communityover 16 years ago
CMS nixes CT colonography screeningover 16 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































